Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 111.64% from the company’s previous close.

Separately, Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Trading Up 0.8 %

Shares of NASDAQ:ATXS traded up $0.06 on Thursday, hitting $7.56. The company had a trading volume of 108,217 shares, compared to its average volume of 299,841. Astria Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.90. The business has a 50 day moving average of $9.21 and a 200 day moving average of $10.60. The company has a market cap of $426.61 million, a PE ratio of -3.62 and a beta of 0.70.

Hedge Funds Weigh In On Astria Therapeutics

Large investors have recently modified their holdings of the company. Quest Partners LLC raised its holdings in shares of Astria Therapeutics by 180.8% in the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,798 shares during the period. PDT Partners LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at about $140,000. SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at about $155,000. Hsbc Holdings PLC purchased a new stake in shares of Astria Therapeutics during the 2nd quarter valued at about $171,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at about $228,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.